Table 4.
Univariate and multivariate analyses of progression‐free and overall survival with first‐line setting
| Characteristic | Subgroups | HR for PFS (95% CI) | HR for OS (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate | P‐value | Multivariate | P‐value | Univariate | P‐value | Multivariate | P‐value | ||
| Age | <65/≥65 years | 1.09 (0.74–1.56) | 0.64 | 0.82 (0.51–1.28) | 0.40 | ||||
| Sex | Male/Female | 1.02 (0.72–1.43) | 0.89 | 1.17 (0.77–1.75) | 0.44 | ||||
| Smoking status | Ever/never | 1.19 (0.83–1.68) | 0.33 | 1.40 (0.93–2.09) | 0.10 | ||||
| ECOG‐PS | 2–4/0–1 | 3.39 (2.12–5.23) | <0.01 | 2.58 (1.49–4.31) | <0.01 | 4.77 (2.87–7.68) | <0.01 | 3.31(1.83–5.79) | <0.01 |
| EGFR‐TKI | Gefitinib or erlotinib/afatinib | 1.82 (1.19–2.90) | <0.01 | 1.65 (1.08–2.65) | 0.01 | 1.87 (1.07–3.54) | 0.02 | 1.61 (0.92–3.07) | 0.09 |
| EGFR mutation | Ex19del or L858R/other | 067 (0.34–1.59) | 0.34 | 0.60 (0.26–1.71) | 0.30 | ||||
| T790M mutation | Yes/No or unknown | 0.86 (0.49–1.40) | 0.57 | 0.45 (0.19–0.92) | 0.02 | 0.55 (0.23–1.12) | 0.10 | ||
| GPS score | 2/0–1 | 2.42 (1.46–3.83) | <0.01 | 1.52 (0.84–2.64) | 0.15 | 4.15 (2.37–6.92) | <0.01 | 2.24 (1.17–4.14) | 0.01 |
CI, confidence interval; EGFR, epidermal growth factor receptor; GPS, Glasgow prognostic score; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; TKI, tyrosine kinase inhibitor.